• Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial

    Thumbnail Image

    Files

    mdw611.pdf (400.37 KB)

    Date

    2017

    Authors

    Journal Title

    Journal ISSN

    Volume Title

    Publisher

    Access

    openAccess

    Embargo end date

    Citation

    Paz-Ares, L. and Tan, E.-H. and O'Byrne, K. and Zhang, L. and Hirsh, V. and Boyer, M. and Yang, J.C.-H. and Mok, T. and Lee, K.H. and Lu, S. and Shi, Y. and Lee, D.H. and Laskin, J. and Kim, D.-W. and Laurie, S.A. and K??lbeck, K. and Fan, J. and Dodd, N. and M??rten, A. and Park, K., Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial, Annals of Oncology, 28, 2, 2017, 270-277

    Abstract

    Description

    URI

    http://hdl.handle.net/2262/82626

    Collections

    Clinical Medicine (Scholarly Publications)
    RSS Feeds

    Endorsement

    Review

    Supplemented By

    Referenced By

    Keywords

    Cancer
    Author's Homepage: http://people.tcd.ie/obyrneke

    Author: O'BYRNE, KEN

    Type of material: Journal Article